Abstinence scoring algorithms for treatment of neonatal opioid withdrawal syndrome (NOWS)

J Perinatol. 2024 Aug;44(8):1132-1136. doi: 10.1038/s41372-024-01895-6. Epub 2024 Feb 16.

Abstract

Objective: Chervoneva et al. (2020) developed an abbreviated score (sMNAS-9) derived from full modified Finnegan MOTHER NAS scale (MNAS) for evaluating severity of NOWS. We sought to develop NOWS treatment algorithms for clinical decision rules based on scores utilizing the shorter sMNAS.

Study design: This was a retrospective study of 373 infants with NOWS scored with MNAS and treated with morphine between 2007 and 2016. The infants were randomly split into training/test sets. The training set was used to derive optimized cutoff values for sMNAS-9 scores. The independent set evaluated the sMNAS-9 clinical decision rules based on full MNAS in NOWS morphine and buprenorphine treatment algorithms.

Result: Clinical decision rules based on sMNAS-9 yielded sensitivities of 88% or higher and specificities of 85% or higher for predicting the respective rules based on full MNAS.

Conclusion: The sMNAS-9 scoring instrument is expected to yield similar clinical decisions in treatment of NOWS.

MeSH terms

  • Algorithms*
  • Analgesics, Opioid / therapeutic use
  • Buprenorphine* / therapeutic use
  • Clinical Decision Rules
  • Female
  • Humans
  • Infant, Newborn
  • Male
  • Morphine* / therapeutic use
  • Neonatal Abstinence Syndrome* / diagnosis
  • Neonatal Abstinence Syndrome* / drug therapy
  • Opiate Substitution Treatment / methods
  • Opioid-Related Disorders / drug therapy
  • Retrospective Studies
  • Sensitivity and Specificity
  • Severity of Illness Index

Substances

  • Morphine
  • Buprenorphine
  • Analgesics, Opioid